Breaking News Instant updates and real-time market news.

OXFD

Oxford Immunotec

$12.00

-0.13 (-1.07%)

07:15
02/27/18
02/27
07:15
02/27/18
07:15

Oxford Immunotec sees FY18 revenue $112M-$118M, consensus $118.15M

For full year 2018, the Company expects revenue of between $112 and $118 million, representing 9% - 15% year-over-year growth as reported.

  • 27

    Feb

OXFD Oxford Immunotec
$12.00

-0.13 (-1.07%)

09/28/17
BTIG
09/28/17
INITIATION
BTIG
Buy
Oxford Immunotec initiated with a Buy at BTIG
BTIG analyst Sung Ji Nam started coverage of Oxford with a $21 price target and a Buy rating. The analyst says that the company's recent acquisitions have strengthened its products, while it "has a compelling opportunity" in Lyme disease. The analyst adds that the company's pipeline gives it "many shots on goal." and notes that it already has a product which is generating annual revenue of "close to $100M."
10/31/17
PIPR
10/31/17
NO CHANGE
Target $19
PIPR
Overweight
Oxford Immunotec price target lowered to $19 from $26 at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his estimates for Oxford Immunotec and cut his price target on the stock to $19 from $26 after the company cut its FY17 revenue guidance due to ongoing pressure on the U.S. TB business. However, he keeps an Overweight rating on the stock, saying Oxford will have the benefit of easier comps in 2018 and that its tick borne disease business growth rate looks conservative.
11/01/17
BARD
11/01/17
NO CHANGE
Target $20
BARD
Outperform
Oxford Immunotec weakness overdone, says Baird
Baird analyst Catherine Ramsey Schulte said the weakness in Oxford Immunotec following yesterday's results was overdone. She noted the U.S. TB revenue came in below expectations due to hurricane and immigration headwinds and several pipeline products were either pushed out or canceled. She continues to believe the set up for 2018 is attractive and believes estimates for the company are conservative. Schulte maintained her Outperform rating and lowered her price target to $20 from $22 on Oxford Immunotec shares.
01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Qiagen, DiaSorin partnership could be disruptive to TB market, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Qiagen (QGEN) announced a partnership with DiaSorin to develop an automated QuantiFERONTB test for the LIAISON analyzers, and argues that it could be disruptive to the existing physician office latent TB market. The analyst believes the agreement could put pressure on some of Oxford's (OXFD) business and potentially force the company to sign a similar deal with a different immunoassay provider. Quirk points out that Oxford also announced preliminary Q4 revenue below the Street, and while the company did not explain the weak results, he believes it was from U.S. immigration weakness and China order timing.

TODAY'S FREE FLY STORIES

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

, EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

14:02
07/16/18
07/16
14:02
07/16/18
14:02
Conference/Events
Rice Midstream to host special shareholder meeting »

Special Shareholder…

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

RMP

Rice Midstream

$18.16

0.16 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

CRSP

Crispr Therapeutics

$59.61

-6.13 (-9.32%)

14:01
07/16/18
07/16
14:01
07/16/18
14:01
Periodicals
Crispr Therapeutics tells CNBC does not use methods described in paper »

Crispr Therapeutics told…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$37.79

-0.22 (-0.58%)

14:00
07/16/18
07/16
14:00
07/16/18
14:00
Options
Bullish option play opened in Masco ahead of earnings »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CRSP

Crispr Therapeutics

$59.09

-6.65 (-10.12%)

13:55
07/16/18
07/16
13:55
07/16/18
13:55
Options
Crispr Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
07/16/18
07/16
13:50
07/16/18
13:50
General news
U.S. equities are up from earlier lows »

U.S. equities are up from…

ECA

Encana

$12.84

-0.4 (-3.02%)

13:45
07/16/18
07/16
13:45
07/16/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 09

    Oct

ADS

Alliance Data

$220.17

-23.32 (-9.58%)

13:44
07/16/18
07/16
13:44
07/16/18
13:44
Technical Analysis
Technical Take: Alliance Data comes off the lows of the day »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

CRM

Salesforce

$147.50

-0.18 (-0.12%)

13:39
07/16/18
07/16
13:39
07/16/18
13:39
Hot Stocks
Salesforce announces definitive agreement to acquire Datorama »

Salesforce has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 16

    Aug

YELP

Yelp

$40.33

0.54 (1.36%)

13:35
07/16/18
07/16
13:35
07/16/18
13:35
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBIX

Leading Brands

$1.62

-0.06 (-3.57%)

13:32
07/16/18
07/16
13:32
07/16/18
13:32
Hot Stocks
Leading Brands announces resolution of temporary non-compliance with Nasdaq rule »

Leading Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$22.84

0.2 (0.88%)

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Conference/Events
Stephens agricultural analyst to hold an analyst/industry conference call »

Agriculture, Chemicals,…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

, NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

13:23
07/16/18
07/16
13:23
07/16/18
13:23
Periodicals
Editas tells CNBC 'not specifically concerned about' Crisper study »

Editas Medicine (EDIT)…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.30

-0.33 (-0.48%)

13:19
07/16/18
07/16
13:19
07/16/18
13:19
Periodicals
CVS apologizes after store managers call police on black customer, AP says »

CVS Health is apologizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/16/18
07/16
13:17
07/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/16/18
07/16
13:16
07/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$17.84

0.75 (4.39%)

13:10
07/16/18
07/16
13:10
07/16/18
13:10
Options
Change of sentiment in Pattern Energy »

Change of sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
07/16/18
07/16
13:05
07/16/18
13:05
Conference/Events
The Brookings Institution to hold a conference »

7th Annual Municipal…

C

Citi

$69.22

2.22 (3.31%)

13:04
07/16/18
07/16
13:04
07/16/18
13:04
Hot Stocks
Citi reports June credit loss 2.60% vs. 2.78% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

ORMP

Oramed

$5.89

-0.08 (-1.34%)

13:02
07/16/18
07/16
13:02
07/16/18
13:02
Downgrade
Oramed rating change  »

B. Riley FBR downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$69.21

0.03 (0.04%)

13:01
07/16/18
07/16
13:01
07/16/18
13:01
Hot Stocks
Quidel receives FDA clearance to market Solana Bordetella Complete Assay »

Quidel announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRD

R.R. Donnelley

$5.53

-0.11 (-1.95%)

13:00
07/16/18
07/16
13:00
07/16/18
13:00
Options
4K RR Donnelley and Sons Aug 6 calls trade for 24c »

4K RR Donnelley and Sons…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
07/16/18
07/16
13:00
07/16/18
13:00
General news
Fed Chairman Powell's Monetary Policy testimony Tuesday won't break new ground »

Fed Chairman…

AMD

AMD

$16.85

0.575 (3.53%)

12:59
07/16/18
07/16
12:59
07/16/18
12:59
Hot Stocks
AMD jumps after analyst sees product transition to expand margins »

Shares of chip maker AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORMP

Oramed

$5.89

-0.08 (-1.34%)

12:58
07/16/18
07/16
12:58
07/16/18
12:58
Downgrade
Oramed rating change  »

Oramed downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.